Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day.

Today is December 21st and I'm your health care show host Christine Harajus.

Next week we're going to be replaying our

favorite episodes from last year so for the last time in 2016 I am welcoming our

regular health care contributor at Todd Campbell to the show phoning in.

Hi Todd. Hi happy holidays to you and everyone who's tuning in today. Thank you very

much and happy holidays to you and your family as well.

Thanks I tried to find an ugly holiday sweater to wear it today but unfortunately all I could

find was a red one so I went with that.

Yeah that counts for something.

That's festive.

I'm over here in my black and white checkers, so maybe not as festive.

Just wait until next week though.

Anywho, so we've been pretty newsy on our health care show lately.

And so I figured in keeping with the trend, the first part of our show will be something

interesting from the health care news seen in the past week.

And then after that, we'll move on to a listener question about the 21st Century Cures Act

and also some stock picks for 2017.

So first things first, some exciting Alzheimer's research results from a company called Acadia

Pharmaceuticals came out yesterday. Really really interesting data and I think that it's very helpful to walk investors through both the pluses and potentially the minuses associated with the information that was released by Acadia Pharmaceuticals.

I don't think this is a stock that we talked about in the past on the show Christine to you.

I don't believe that we ever have talked about them, but deal with them, they've got this one drug. It's called Nuplizid and it is already approved for Parkinson's Disease psychosis and now they're testing it in Alzheimer's Disease Psychosis.

...